ストックスクリーナーアプリを入手
436.27
2.35%
-10.51
アフターアワーズ：
436.69
0.42
+0.10%
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Sumitomo Mitsui Trust Group Reduces Vertex Pharmaceuticals Stake - National Today
Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Promising Biotech Stocks To Follow TodayApril 10th - MarketBeat
Vertex Pharmaceuticals (VRTX) Analyst Rating Update: Price Targe - GuruFocus
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Benzinga
RBC Trims Price Target on Vertex Pharmaceuticals to $541 From $543, Keeps Outperform Rating - marketscreener.com
What to Expect From Vertex Pharmaceuticals’ Q1 2026 Earnings Report - Yahoo Finance
Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways - simplywall.st
Vertex licenses Halozyme’s Hypercon platform in $15 million deal - Новости GxP
Vertex Pharmaceuticals (VRTX) Valuation Check After FDA Expands ALYFTREK And TRIKAFTA Use - Yahoo Finance UK
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals Incorporated (VRTX) Is Gaining Attention: Key Information to Consider Before Investing - Bitget
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Halozyme inks license agreement with Vertex - The Pharma Letter
Halozyme and Vertex sign deal for Hypercon technology - Pharmaceutical Technology
Vertex Pharmaceuticals Inc stock: New Halozyme deal signals pipeline push - AD HOC NEWS
Vertex taps Halozyme and its recently acquired Elektrofi tech in $15M drug delivery deal - Fierce Pharma
Vertex Pharma in pact with Halozyme for Hypercon drug delivery tech - Seeking Alpha
Halozyme (HALO) Unveils Partnership with Vertex for Drug Deliver - GuruFocus
Halozyme, Vertex Pharmaceuticals Enter Exclusive Collab & License Agreement - Contract Pharma
Halozyme announces global collaboration and license agreement with Vertex Pharmaceuticals for Hypercon(TM) technology - marketscreener.com
Halozyme Announces Global Collaboration And License Agreement With Vertex Pharmaceuticals For Hypercon™ Technology - TradingView
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology - PR Newswire
Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat - MSN
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vertex Pharmaceuticals Incorporated (VRTX) stock price, news, quote and history - Yahoo Finance UK
Vertex to Announce First Quarter 2026 Financial Results on May 4th - Business Wire
Biotech layoffs pick back up as 14 companies cut 745 jobs in Q1 - The Business Journals
Best Biotech Stocks To Follow NowApril 5th - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insider Sell: Joy Liu Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals EVP Sells $439,288 in Stock - National Today
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $439,288.26 in Stock - MarketBeat
Vertex (VRTX) legal chief sells 978 shares under 10b5-1 plan - Stock Titan
Vertex Pharmaceuticals Inc (VX1.MU) Stock Forum & Discussion - Yahoo! Finance Canada
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Growth and Technical Setup - ChartMill
Aberdeen Group Reduces Stake in Vertex Pharmaceuticals - National Today
Aberdeen Group plc Has $118.81 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
[ARS] VERTEX PHARMACEUTICALS INC / MA SEC Filing - stocktitan.net
Vertex (NASDAQ: VRTX) posts $12B 2025 revenue and sets 2026 proxy votes - Stock Titan
Vertex Pharmaceuticals: Label Expansions For ALYFTREK & TRIKAFTA Plus Strong Demand (VRTX) - Seeking Alpha
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday - AOL.com
The Opioid Crisis Was an Innovation Failure. Vertex Just Showed a Way to Fix It - inc.com
F&V Capital Management LLC Buys Shares of 3,645 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Allspring Global Investments Holdings LLC Cuts Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Banque Pictet & Cie SA - MarketBeat
Vertex Advances FDA Filing for IgA Nephropathy Therapy - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Submits Biologics Licensing Application for Accelerated FDA Approval - GuruFocus
Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision - Yahoo Finance
Vertex Pharmaceuticals (NASDAQ: VRTX) reports 978-share Rule 144 resale and insider sales - Stock Titan
FDA Expands Vertex (VRTX) Drugs' Usage for Cystic Fibrosis - GuruFocus
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval of Expanded Use of ALYFTREK (Vanzacaftor/Tezacaftor/Ivacaftor) - marketscreener.com
Vertex Pharmaceuticals IncFDA expands indication for trikafta in cf patients ages 2 and older - marketscreener.com
Vertex wins FDA label expansion for cystic fibrosis drugs - Seeking Alpha
, Expanding Availability of These Medicines to ~95% of All People With CF in the United States - Business Wire
Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Performance Indicators - Markets Mojo
2.47%
0.26%
大文字化:
|
ボリューム (24 時間):